In recent studies by Eberly et al [53] and Waldrop et al [54], men were less likely than women to be treated with a GLP-1 medication and Black and Latino patients with diabetes were 19% and 9%, respectively, less likely to be treated with a GLP-1 medication as compared with their White counterparts. This evidence concerns the gene GCG and diabetes mellitus.